Lucid Diagnostics Inc. (LUCD)
1.53
-0.06 (-3.77%)
At close: Feb 20, 2025, 3:59 PM
1.49
-2.63%
After-hours: Feb 20, 2025, 05:30 PM EST
undefined% (undefined)
| Bid | 1.48 |
| Market Cap | 90.81M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.12 |
| PE Ratio (ttm) | -1.37 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 1.54 |
| Volume | 649,564 |
| Avg. Volume (20D) | 507,847 |
| Open | 1.59 |
| Previous Close | 1.59 |
| Day's Range | 1.36 - 1.60 |
| 52-Week Range | 0.63 - 1.63 |
| Beta | undefined |
About LUCD
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an...
Industry Medical - Devices
Sector Healthcare
IPO Date Oct 14, 2021
Employees 70
Stock Exchange NASDAQ
Ticker Symbol LUCD
Website https://www.luciddx.com
Analyst Forecast
According to 4 analyst ratings, the average rating for LUCD stock is "Buy." The 12-month stock price forecast is $2.5, which is an increase of 63.37% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
Lucid Diagnostics Inc. is scheduled to release its earnings on Mar 24, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 months ago
+5.95%
Lucid Diagnostics shares are trading higher after ...
Unlock content with
Pro Subscription
6 months ago
-2.1%
Lucid Diagnostics shares are trading lower after the company announced the publication of its analytical validation study for the early detection of Esophageal cancer.
